Selventa

Genstruct Appoints David de Graaf as Chief Scientific Officer

Genstruct Appoints David de Graaf as Chief Scientific Officer

June 1, 2010

Renowned Systems Biology Expert to Lead Company’s Scientific Initiatives

CAMBRIDGE, Mass., June 1, 2010 – Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better develop novel therapeutics, molecular diagnostics and patient-specific therapies, today announced that it has appointed industry expert, David de Graaf, Ph.D., as its chief scientific officer (CSO).

Joule Unlimited, Inc.

Joule Elects Ruben Vardanian to Board of Directors

Joule Elects Ruben Vardanian to Board of Directors

June 3, 2010

Cambridge, Mass. – June 3, 2010 – Joule Unlimited, Inc. today announced the election of Ruben Vardanian to its board of directors, gaining the strategic insight of a highly-accomplished, international business leader.

Selventa

Genstruct Appoints David de Graaf as Chief Scientific Officer

Genstruct Appoints David de Graaf as Chief Scientific Officer

June 1, 2010

Renowned Systems Biology Expert to Lead Company’s Scientific Initiatives

CAMBRIDGE, Mass., June 1, 2010 – Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better develop novel therapeutics, molecular diagnostics and patient-specific therapies, today announced that it has appointed industry expert, David de Graaf, Ph.D., as its chief scientific officer (CSO).

Mascoma Corporation

Mascoma Corporation Adds Jim Schumacher as Vice President, Business Development

Mascoma Corporation Adds Jim Schumacher as Vice President, Business Development

August 2, 2007

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mascoma Corporation, a leader in low-carbon cellulosic biomass-to-ethanol production through advanced biotechnology, today announced that Jim Schumacher has joined the company as Vice President, Business Development. In this role, Mr. Schumacher will lead business development activities and negotiations for domestic and foreign opportunities. He will also oversee key strategic partnerships and merger and acquisition activities for the firm.

BG Medicine, Inc.

BG Medicine Files US Registration Statement with SEC in Support of Euronext Amsterdam IPO

BG Medicine Files US Registration Statement with SEC in Support of Euronext Amsterdam IPO

August 6, 2007

WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine, Inc. today announced it has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission (SEC) for a proposed Initial Public Offering (IPO) of its common stock. All of the shares to be offered will be sold by the company. The number of shares to be sold and the price range for the offering have not yet been determined. BG Medicine intends to apply for its common stock to list and trade on Euronext Amsterdam by NYSE Euronext under the symbol “BGMDX”.

Epitome Biosystems

Epitome Biosystems Launches Ti-Tyr™ Profiling Chips for Simultaneous Measurement of Multiple Cellular Events

Epitome Biosystems Launches Ti-Tyr™ Profiling Chips for Simultaneous Measurement of Multiple Cellular Events

August 7, 2007

Waltham, MA, August 7, 2007 – Epitome Biosystems announced today the commercial launch of its Ti-Tyr™ Phosphorylation Profiling Chip, providing researchers with substantially increased capabilities for measuring cellular activities in their drug discovery and development efforts. Ti-Tyr™ Chips enable specific, cell-based measurements of biological function to be made quickly and in a highly multiplexed format, increasing the amount of relevant data generated per sample.

LS9

LS9, Inc., the Renewable Petroleum Company™, Adds Charles Cooney to Board of Directors

LS9, Inc., the Renewable Petroleum Company™, Adds Charles Cooney to Board of Directors

August 8, 2007

SAN CARLOS, Calif., Aug. 8 /PRNewswire/ -- LS9, Inc., the Renewable Petroleum Company™, today announced that the company has appointed Charles L. Cooney to its Board of Directors. Dr. Cooney's extensive manufacturing and scale-up expertise, along with his business-building and corporate governance experience, will significantly contribute to the rapid commercialization of LS9 DesignerBiofuels™ products.

Adnexus Therapeutics

Adnexus Therapeutics Raises $15.5 Million in Series C Funding

Adnexus Therapeutics Raises $15.5 Million in Series C Funding

August 9, 2007

New Investor HBM BioVentures, Prominent Global Venture Firm, Leads Round

Waltham, MA – August 9, 2007 – Adnexus Therapeutics, Inc. today announced that it has raised $15.5 million through a private placement of Series C Preferred Stock. The financing was led by a new investor, HBM BioVentures (Cayman) Ltd., a leading global healthcare investment firm. All of Adnexus’ existing venture investors, Atlas Venture, Flagship Ventures, Polaris Venture Partners and Venrock, participated in the financing.

Technology Review Reveals the 2007 TR35 List of the 35 Top Young Innovators Under 35

Technology Review Reveals the 2007 TR35 List of the 35 Top Young Innovators Under 35

August 15, 2007

2007 Emerging Technologies Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Technology Review today announced the TR35 for 2007 – 35 accomplished men and women under the age of 35 who exemplify the spirit of innovation in business, technology and the arts. Doing ground-breaking work in energy, nanotechnology, biotechnology, computing, medicine, telecommunications and the Web, these young individuals stand out for their unique contributions to society.

Technology Review Unveils the 2007 TR35 Humanitarian and Innovator of the Year

Technology Review Unveils the 2007 TR35 Humanitarian and Innovator of the Year

August 15, 2007

Tapan Parikh from the University of Washington Named Humanitarian of the Year; David Berry of Flagship Ventures Named Innovator of the Year

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Technology Review today announced the 2007 Humanitarian and Innovator of the Year as part of its annual TR35 awards honoring the top 35 innovators under the age of 35. The Humanitarian of the Year honor goes to Tapan Parikh at the University of Washington, and the Innovator of the Year is David Berry, a principal at Flagship Ventures.